Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-112091
Filing Date
2025-05-05
Accepted
2025-05-05 08:00:15
Documents
20
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A d875647ddef14a.htm   iXBRL DEF 14A 397956
3 GRAPHIC g875647dsp001a.jpg GRAPHIC 27982
4 GRAPHIC g875647dsp001b.jpg GRAPHIC 1373
5 GRAPHIC g875647dsp001c.jpg GRAPHIC 1244
6 GRAPHIC g875647dsp001d.jpg GRAPHIC 1335
7 GRAPHIC g875647dsp001e.jpg GRAPHIC 1450
8 GRAPHIC g875647dsp002.jpg GRAPHIC 893
9 GRAPHIC g875647dsp002a.jpg GRAPHIC 2181
10 GRAPHIC g875647dsp002b.jpg GRAPHIC 1059
11 GRAPHIC g875647g81k15.jpg GRAPHIC 55398
  Complete submission text file 0001193125-25-112091.txt   877840

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fhtx-20241231.xsd EX-101.SCH 2500
22 EXTRACTED XBRL INSTANCE DOCUMENT d875647ddef14a_htm.xml XML 1248
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39634 | Film No.: 25910956
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)